667 related articles for article (PubMed ID: 35024184)
1. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism.
Wang S; Sheng F; Zou L; Xiao J; Li P
J Adv Res; 2021 Dec; 34():109-122. PubMed ID: 35024184
[TBL] [Abstract][Full Text] [Related]
2. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
[TBL] [Abstract][Full Text] [Related]
3. Policosanol alleviates hepatic lipid accumulation by regulating bile acids metabolism in C57BL6/mice through AMPK-FXR-TGR5 cross-talk.
Zhai Z; Niu KM; Liu H; Lin C; Tu Y; Liu Y; Cai L; Ouyang K; Liu J
J Food Sci; 2021 Dec; 86(12):5466-5478. PubMed ID: 34730235
[TBL] [Abstract][Full Text] [Related]
4. Triglycerides and gallstone formation.
Smelt AH
Clin Chim Acta; 2010 Nov; 411(21-22):1625-31. PubMed ID: 20699090
[TBL] [Abstract][Full Text] [Related]
5. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases.
Guan B; Tong J; Hao H; Yang Z; Chen K; Xu H; Wang A
Acta Pharm Sin B; 2022 May; 12(5):2129-2149. PubMed ID: 35646540
[TBL] [Abstract][Full Text] [Related]
6. Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.
Kwong E; Li Y; Hylemon PB; Zhou H
Acta Pharm Sin B; 2015 Mar; 5(2):151-7. PubMed ID: 26579441
[TBL] [Abstract][Full Text] [Related]
7. Bile acids are nutrient signaling hormones.
Zhou H; Hylemon PB
Steroids; 2014 Aug; 86():62-8. PubMed ID: 24819989
[TBL] [Abstract][Full Text] [Related]
8. Effect of exogenous bile salts supplementation on the performance and hepatic lipid metabolism of aged laying hens.
Sun L; Xin Q; Jiao H; Wang X; Zhao J; Li H; Zhou Y; Cao A; Wang J; Lin H
J Anim Sci; 2023 Jan; 101():. PubMed ID: 37773415
[TBL] [Abstract][Full Text] [Related]
9. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
Li X; Zhao W; Xiao M; Yu L; Chen Q; Hu X; Zhao Y; Xiong L; Chen X; Wang X; Ba Y; Guo Q; Wu X
J Ethnopharmacol; 2022 Aug; 294():115333. PubMed ID: 35500802
[TBL] [Abstract][Full Text] [Related]
10. Bile acid nuclear receptor FXR and digestive system diseases.
Ding L; Yang L; Wang Z; Huang W
Acta Pharm Sin B; 2015 Mar; 5(2):135-44. PubMed ID: 26579439
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.
Mueller M; Thorell A; Claudel T; Jha P; Koefeler H; Lackner C; Hoesel B; Fauler G; Stojakovic T; Einarsson C; Marschall HU; Trauner M
J Hepatol; 2015 Jun; 62(6):1398-404. PubMed ID: 25617503
[TBL] [Abstract][Full Text] [Related]
12. Bisphenol A induced hepatic steatosis by disturbing bile acid metabolism and FXR/TGR5 signaling pathways via remodeling the gut microbiota in CD-1 mice.
Hong T; Zou J; He Y; Zhang H; Liu H; Mai H; Yang J; Cao Z; Chen X; Yao J; Feng D
Sci Total Environ; 2023 Sep; 889():164307. PubMed ID: 37211107
[TBL] [Abstract][Full Text] [Related]
13. Astragalus polysaccharide attenuates nonalcoholic fatty liver disease through THDCA in high-fat diet-fed mice.
Zheng N; Wang H; Zhu W; Li Y; Li H
J Ethnopharmacol; 2024 Feb; 320():117401. PubMed ID: 37967775
[TBL] [Abstract][Full Text] [Related]
14. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
[TBL] [Abstract][Full Text] [Related]
15. Lactoferrin promotes bile acid metabolism and reduces hepatic cholesterol deposition by inhibiting the farnesoid X receptor (FXR)-mediated enterohepatic axis.
Ling CJ; Xu JY; Li YH; Tong X; Yang HH; Yang J; Yuan LX; Qin LQ
Food Funct; 2019 Nov; 10(11):7299-7307. PubMed ID: 31626262
[TBL] [Abstract][Full Text] [Related]
16. Bile acids as regulators of hepatic lipid and glucose metabolism.
Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
[TBL] [Abstract][Full Text] [Related]
17. Ganoderma Lucidum Polysaccharide Peptide Alleviates Hepatoteatosis via Modulating Bile Acid Metabolism Dependent on FXR-SHP/FGF.
Zhong D; Xie Z; Huang B; Zhu S; Wang G; Zhou H; Lin S; Lin Z; Yang B
Cell Physiol Biochem; 2018; 49(3):1163-1179. PubMed ID: 30196282
[TBL] [Abstract][Full Text] [Related]
18. Targeting mTOR/YY1 signaling pathway by quercetin through CYP7A1-mediated cholesterol-to-bile acids conversion alleviated type 2 diabetes mellitus induced hepatic lipid accumulation.
Yang T; Wang Y; Cao X; Peng Y; Huang J; Chen L; Pang J; Jiang Z; Qian S; Liu Y; Ying C; Wang T; Zhang F; Lu Q; Yin X
Phytomedicine; 2023 May; 113():154703. PubMed ID: 36889164
[TBL] [Abstract][Full Text] [Related]
19. The protective mechanism of Lactobacillus plantarum FZU3013 against non-alcoholic fatty liver associated with hyperlipidemia in mice fed a high-fat diet.
Chen M; Guo WL; Li QY; Xu JX; Cao YJ; Liu B; Yu XD; Rao PF; Ni L; Lv XC
Food Funct; 2020 Apr; 11(4):3316-3331. PubMed ID: 32226996
[TBL] [Abstract][Full Text] [Related]
20. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]